Scientists from the National University of Singapore and Central South University have engineered gut bacteria that enhance immune response against colorectal cancer. This synthetic biology advancement represents a novel immunotherapeutic strategy aimed at improving survival outcomes in colorectal cancer patients by modulating the gut microbiome to activate antitumor immunity, illustrating the potential of microbiome engineering in oncology.